We hereby attaching you the BM outcome
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Oxygenta Pharmaceutical Ltd announced on June 20, 2025, that Virupaksha Organics Limited has successfully completed its open offer and taken control of the company as the new promoter. Following this change in management, the board was completely reconstituted. Six new directors were appointed — two as Executive Directors (Chandra Mouliswar Reddy Gangavaram and Balasubba Reddy Mamilla), one as Non-Executive Director (Vedavathi Gangavaram), and three as Independent Directors (Veera Reddy Arava, Sidda Reddy Kanuparthi, and Sharvari Swapnil Shinde), each for a 5-year term. At the same time, all six previous directors resigned, including three Executive Directors and three Independent Directors. Sai Sudhakar Vankineni continues as Managing Director & CFO, and Sanagari Kondal Reddy continues as a Non-Executive Independent Director. The Audit, Nomination & Remuneration, and Stakeholders Relationship Committees were also reconstituted with the new board.
This is a major ownership change — Virupaksha Organics Limited is now the controlling promoter of Oxygenta Pharmaceutical, which will likely lead to changes in business strategy and operations. For shareholders, the complete board overhaul signals a fresh start under new management, and stock price may react to the new promoter's plans and track record.